Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia (vol 397, pg 671, 2021)

Logunov D. Y.; Dolzhikova I. V; Shcheblyakov D. V

首页> 外文期刊>The Lancet >Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia (vol 397, pg 671, 2021)

【24h】

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia (vol 397, pg 671, 2021)

机译：RAD26和RAD5基于载体的异源素质 - 增压Covid-19疫苗的安全性和有效性：俄罗斯随机对照第3阶段试验的临时分析（Vol 397，PG 671,2021）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2021年第10275期|共1页
作者
Logunov D. Y.; Dolzhikova I. V; Shcheblyakov D. V;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献

1. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia [J] . Logunov Denis Y., Dolzhikova Inna V., Shcheblyakov Dmitry V., The Lancet . 2021,第10275期

机译：RAD26和基于RAD5载体的异源素质促进Covid-19疫苗的安全性和有效性：俄罗斯随机对照第3阶段试验的临时分析
2. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia (vol 396, pg 887, 2020) [J] . Logunov D. Y., Dolzhikova I. V, Zubkova O. V The Lancet . 2021,第10269期

机译：rad26和rad5载体的异源素母型促进咖啡酰-19两种配方的安全性和免疫原性：来自俄罗斯的两个开放式，非随机阶段1/2研究（Vol 396，PG 887,2020）
3. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (vol 397, pg 99, 2021) [J] . Voysey M., Clemens S. A. C., Madhi S. A. The Lancet . 2021,第10269期

机译：Chadox1 NCoV-19疫苗（AZD1222）对SARS-COV-2的安全性和有效性：巴西和英国四次随机对照试验的临时分析（Vol 397，PG 99,2021）
4. A randomized double-blind placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated Vero cell): a structured summary of a study protocol for a randomised controlled trial [O] . Murat Akova, Serhat Unal 2021

机译：随机双盲安慰剂对照期III临床试验评价SARS-COV-2疫苗（灭活VERO细胞）的功效和安全性：随机对照试验的研究方案的结构性概述
5. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia [O] . Denis Y Logunov, Inna V Dolzhikova, Olga V Zubkova, 2020

机译：rad26和rad5载体的异源素母素升压Covid-19的安全性和免疫原性两种配方：来自俄罗斯的两个开放，非随机化阶段1/2研究

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia (vol 397, pg 671, 2021)

著录项

相似文献

相关主题

期刊订阅